Intravenous tocilizumab is currently dosed on body weight, although a weak correlation between body weight and clearance has been described. The aim of the study was to assess the current dosing strategy and provide a scientific rational for dosing using a modelling and simulation approach.
Introduction
Biological therapies are recommended for patients with rheumatoid arthritis (RA) with a nonsatisfactory response to synthetic conventional disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine and leflunomide.
Tocilizumab is a humanized monoclonal antibody that has demonstrated its efficacy in the treatment of RA by competitively inhibiting interleukin 6 binding to both its soluble and membrane receptors, thus preventing its proinflammatory activity [1] [2] [3] [4] .
Currently, tocilizumab is available as intravenous (IV) infusion and subcutaneous injection. Different tocilizumab starting doses have been approved by the European and US regulatory agencies [5, 6] . Furthermore, there is a trend in clinical practice to implement dose de-escalation strategies in patients with RA who are in sustained remission, to improve the risk/benefit ratio and reduce costs [7, 8] . Dose reductions are performed empirically mainly due to the lack of consistent pharmacokinetic (PK) studies that would help to assist in dosing recommendations. Moreover, recommended dosing regimens for IV administration are based on body weight whereas a fixed dosing is recommended for the subcutaneous administration. A fixed dosing approach is feasible for monoclonal antibodies since, in general, most of them are target specific, have a relatively large therapeutic window and body size is of minor influence on drug exposure.
To date, IV tocilizumab effectiveness has been shown to be superior when administered at a dose of 8 mg kg -1 compared to 4 mg kg -1 [9] [10] [11] [12] and in those individuals who achieve a cumulative area under the curve (cAUC) at 24 weeks of treatment above 100 × 10 3 μg h ml -1 [13] .
Moreover, a population PK study [14] associated tocilizumab clearance (CL) with body surface area, showing that patients with a higher body surface area had a higher drug CL. In addition, body weight also affected CL. However, differences in body weight translated only into minor changes in CL, making it potentially clinically irrelevant. Therefore, a dosing approach based on a fixed (weight independent) tocilizumab dose is likely to be beneficial as it may show reduced PK variability and its preparation is much more convenient, cheaper and less-error prone.
The aim of this study was to assess the current dosing strategy of IV tocilizumab in patients with RA and to provide a scientific rational for dosing using a modelling and simulation approach.
Methods

Patients
This study is a prospective, observational, single-centre study conducted in the Arthritis Unit (Rheumatology Service) of the Hospital Clinic of Barcelona, a university tertiary hospital. The protocol (code HCB/2015/0533) was approved by the hospital ethics committee and was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Before inclusion in the study, all patients provided written informed consent. Subjects eligible to participate in the study needed to be aged at least 18 years with diagnosis of RA, treated with IV tocilizumab and to have received a minimum of three doses of the study drug. Exclusion criteria were hypersensitivity to tocilizumab, pregnancy, active severe infections, hepatic enzyme alteration (>5 times the superior limit of normality), absolute neutrophil count <0.5 × 10 9 l -1 or a platelet count <50 × 10 9 l -1 . Enrolled subjects received treatment with a 1-h infusion of IV tocilizumab at a dose range of 4, 6 or 8 mg kg -1 every 28 days at the discretion of the treating physician.
Data
Demographic characteristics, such as age, sex, race, total body weight, height and smoking habit were recorded in the first evaluation. Clinical laboratory measurements including serum creatinine, creatinine clearance (estimated according to the Cockcroft-Gault formula [15] ), haematocrit, total serum proteins, albumin, high-density lipoprotein-cholesterol, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were documented at the moment of inclusion. Blood samples were collected to measure trough concentrations (just before the next drug dose) and, when possible, once a week until the next drug administration. Serum was obtained and stored at -80°C until analysis. Tocilizumab concentrations were determined in the Immunology Department, CDB, Hospital Clinic, using the LisaTracker Tocilizumab Kit (Ref. LTT 002-96), ThearaDiag, France, following manufacturer's instructions. The limit of detection of the assay was 1 μg ml -1 and the lower and upper limits of quantification were 1 and 50 μg ml -1 , respectively. Clinical efficacy was assessed at the visit of inclusion by a rheumatologist through the measurement of the different variables that compose the most used composite indexes: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI). Therefore, the number of swollen and tender joint counts, patient and physician global assessment of disease activity and pain patient assessment were recorded.
PK analysis
Nonlinear mixed effects modeling was performed using NONMEM v.7.3 (Icon Development Solutions) [16] , following a three-step strategy: (i) basic population model selection; (ii) covariate selection; and (iii) model evaluation. The firstorder conditional estimation with interaction (FOCEi) method was used for parameter estimation. The program Pirana version 2.9.5 was used as an interface for NONMEM and for run deployment [17] . Models of one and two compartments with first-order elimination were explored during the structural model development. Interindividual variability [18] was evaluated for all PK parameters. Additive, proportional and combined error models were tested for residual variability on drug concentrations.
Goodness of fit for a given model was assessed by changes in the NONMEM minimum objective function value (equal to -2log likelihood) and plots of population and individual predicted concentrations vs. observed tocilizumab concentrations. The residual error components of models were assessed via scatter plots of conditional weighted residuals vs. predicted concentrations and time [19, 20] . Changes in the standard error of parameter estimates (precision) was also assessed. The minimal value of the objective function provided by NONMEM was used to discriminate between hierarchical models. A P value of 0.05, corresponding with a change in objective function of 3.84 points with one degree of freedom was considered statistically significant. R version 3.2.2 and the package Xpose4 version 4.5.3 were used to guide further model building process [21, 22] . Pearlspeaks-NONMEM (PsN) version 5.24 was used for automation throughout the modelling process [23] .
In the second step, baseline demographic covariates (age, sex, ethnicity, body weight, height and smoking), baseline laboratory covariates (creatinine clearance, haematocrit, total serum proteins, albumin and high-density lipoproteincholesterol) and baseline biomarker covariates (rheumatoid factor, anti-CCP, anti-drug antibodies and serum calprotectin) were included in the covariate analysis. The influence of time-varying covariates such as CRP and ESR were also assessed. Covariates were entered by the cumulative forward inclusion/backward elimination procedures in NONMEM. A covariate was retained if it led to a significantly improved fit (P < 0.05, likelihood ratio test). Biological plausibility of the covariate, graphical displays based on the agreement between the observed and predicted drug concentrations and the uniformity of the distribution of the residuals were also considered for covariate inclusion. The extent of Bayesian shrinkage in the PK parameters was evaluated for each parameter in the final model [24] .
The internal evaluation of the PK model was assessed by graphical and statistical methods, including visual predictive checks [25] . Bootstrap resampling technique (with replacement) was used to build confidence intervals (CIs) of PK parameter estimates [26] . The final model was fitted to the replicate data sets (2000 data sets) and parameter estimates were obtained for each of them. Median and 95% CIs values of the bootstrap sample estimates were compared with those estimated from the original data. In case of wide CI values, a sensitivity analysis was conducted to assess the robustness of the estimation of the parameter.
Dosage regimen simulations
Monte Carlo simulations using the final population PK model of IV tocilizumab were performed to assess whether the bodyweight dosing or fixed dosing was more appropriate. Therefore, the cAUC at 24 weeks of treatment was calculated with the two approaches using a random uniform distribution with a body weight between 40 and 120 kg: (i) 1000 patients were simulated after IV tocilizumab was administered at the doses of 8, 6 and 4 mg kg -1 every 28 days for 24 weeks; (ii) 1000 patients were simulated after IV tocilizumab was administered at the doses of 560, 420 and 280 mg every 28 days for 24 weeks. Fixed doses were calculated from the body-weight dosing recommendations considering a standard subject of 70 kg. All simulations were performed without considering the influence of CRP on tocilizumab CL and in a situation of systemic inflammation (CRP value of 2.8 mg dl -1 , according to mean patients' CRP baseline values in tocilizumab clinical trials) [1, 2, 4] .
Statistical analysis
Statistical analysis was performed using R version 3.2.2. [21] Means, medians, standard deviations (SDs), 95% confidence intervals (95% CIs), and quartiles were calculated for continuous variables. The Student t test was used for comparisons of normally distributed variables and the Mann-Whitney U test was used for comparisons of non-normally distributed variables. Results are expressed as absolute and relative frequencies for categorical variables, and the chi-square test was used to compare them. The significance level for all analyses was defined by a P value of <0.05.
Results
Patients and samples
Thirty-five subjects were included in the study; 31 (88.6%) were women. Mean (± SD) age was 54.1 (± 12.3) years and mean (± SD) total body weight was 63 (± 13.8) kg. Twenty patients were receiving concomitant treatment with steroids and 24 with synthetic conventional diseasemodifying antirheumatic drugs (see Table 1 for further detail). Fifty-four percent of the patients received a dosage of 8 mg kg -1 of IV tocilizumab (n = 19). The remaining patients were on reduced-dose regimens: 6 mg kg -1
(n = 8) and 4 mg kg -1 (n = 8). Detailed patient characteristics and laboratory parameters are shown in Table 1 . According to DAS28 status, 74%, 11% and 14% of patients were in remission, low disease activity and moderate activity, respectively. The percentages according to SDAI and CDAI were 9%, 49%, 37% and 6%, and 11%, 46%, 26% and 17%, respectively, for remission, low, moderate and high disease activity. A total of 109 blood samples were obtained during the study period. Fifty-four samples correspond to trough concentrations and the rest correspond to intermediate time points between two drug administrations (approximately at 7, 14 and 21 days after drug infusion). Sixteen patients participated with a single blood sample and the remaining 19 with an average of five samples per patient.
ADAs were tested in all samples with tocilizumab levels <1 μg ml -1 (n = 17), but they were not detected in any of them.
Population PK model
Tocilizumab serum concentrations were best described by a one-compartment disposition model with parallel first order (linear) and Michaelis-Menten (nonlinear) elimination kinetics. Interindividual variability was incorporated into the CL and volume of distribution (V) parameters. Residual variability was characterized by a combined error model with an additive part of 0.161 μg ml -1 (expressed as the SD) and a proportional part of 25.5% (expressed as the coefficient of variation). The covariates selected to be included in the final model were the effect of total body weight and CRP levels on CL (P < 0.05). The PK model for CL was expressed as the following:
An increase in weight from 40 to 120 kg led to a 49% increase in CL and an increase of CRP levels from 0.1 to 20 mg dl -1 led to a 275% increase in CL.
The diagnostic plots for the basic and final PK model indicated that the observed and predicted data were in good agreement with symmetrical distribution in the conditional weighted residual plots. The model parameters had reasonable levels of η-shrinkage for CL (33.9%) and V (16.1%). An overview of the PK parameter estimates from the final population PK model is presented in Table 2 . Weight, Mean ± SD 63.5 ± 13.8
Height, Mean ± SD 161 ± 8.10
Disease duration in years, Median (range) 11.1 (2.90À48.5)
Days from last tocilizumab dose, Mean ± SD Laboratory data, mean ± SD 
Model evaluation
The visual predictive checks indicated adequate goodness-offit ( Figure 1 ). The statistical distributions of the parameter estimates obtained from the bootstrap analysis are shown in Table 2 . The median values of the parameters estimated from the bootstrap analysis were in good agreement with the point estimates and the 95% CIs were reasonably narrow, demonstrating satisfactory precision, except for Michaelis-Menten constant (K M ) CI, which was expected to be wider since information on target binding was lacking. High standard error values for some of the parameter estimated can be explained by sparse data, a common situation in studies conducted in the clinical practice setting. Visual and numerical predictive checks demonstrated good predictive performance of the final PK model ( Figure 1 ).
Dosage regimen simulation
Results from the performance of the two tested approaches (body weight and fixed dosing) are displayed in Table 3 , with mean simulated values for cAUC, maximum concentration (C max ) and minimum concentration (C min ) for each of them. As expected, cAUC, C max and C min increased with increasing tocilizumab dose and the nonlinear CL of tocilizumab led to a greater than dose-proportional increase in all values. Additionally, we observed a decrease in all PK measures of 19%, 4% and 54% for cAUC, C max and C min respectively, when simulations are performed with a CRP value of 2.8 mg dl -1 (Table 4) . Box plots showing the results from 1000 simulations from our final population PK model, without considering the influence of CRP, for body-weight dosing and fixed-dosing strategies are depicted in Figure 2 . The percentage of patients attaining the target (defined as a cAUC at 24 weeks of treatment >100 × 10 3 μg h ml -1 ) [13] with each dosing strategy and considering the influence of CRP is provided in Figure 3 . The usual regimen of 8 mg kg -1 every 28 days shows a target attainment in 99.8% of the subjects, being 1.9% of the subjects with extreme low weight (<50 kg) at risk of underdosing (mean cAUC ± SD: 142.6 ± 23.0). Patients from weights of 60-120 kg are far above the cAUC efficacy threshold. By contrast, using a fix dose of 560 mg of IV tocilizumab, the totality of individuals would be above the target regardless of their weight and showing a narrower range and more consistent drug exposure along weight groups.
With reduced doses of 6 mg kg -1 of tocilizumab, a lower fraction (90.5%) of subjects would achieve the target compared with the full tocilizumab dose. Again, patients with lower weights are at risk of underdosing, with percentages of 32.6 and 20.6 if weight is between 40-49 kg and 50-59 kg, respectively. A comparable tocilizumab fix dose of 420 mg allows a more homogeneous distribution of patients reaching the therapeutic target (99.7%) with a maximum percentage of 1.5% of patients at risk of underdosing in extreme overweight patients (>110 kg). Finally, with the reduced dose of tocilizumab of 4 mg kg -1 , 52.2% of the subjects would reach the target and >30% of individuals in the weight category between 40 and 89 kg would be underdosed. A fix dose of 280 mg provides a cAUC value above the target for 17.9% of the subjects, relatively independent of weight.
Simulating the same dosing approaches but considering a systemic inflammatory status with CRP levels of 2.8 mg dl -1 , showed a similar pattern across different body weight categories but with a lower percentage of patients reaching the PK target as expected ( Figure 3 , right column).
Discussion
Simulations confirm that the fixed-dosing approach for IV tocilizumab reduces variability in tocilizumab exposure among weight categories compared to the current weightbased dosing approach. In this study, we used mixed effects modelling to characterize the PK of the drug and to investigate quantitative relationships between the PK parameters and physiological and/or demographic features of subjects with RA disease who were treated with IV tocilizumab. The serum concentration-time courses for the collected data were best described by an open one-compartment PK model with parallel linear and nonlinear elimination. Although antibodies PK has usually been described using two-compartment models, when the sampling strategy is insufficient, such as the lack of intense sampling just after the drug infusions as in our Table 3 Intravenous tocilizumab steady state values for cumulative area under the curve, maximum and minimum concentration at 24 weeks of treatment for body-weight dosing and fixed dosing (results from 1000 simulations) without considering the influence of C-reactive protein Table 4 Intravenous tocilizumab steady state values for cumulative area under the curve, maximum and minimum concentration at 24 weeks of treatment for body-weight dosing and fixed dosing (results from 1000 simulations) considering the influence of C-reactive protein with a value of 2.8 mg dl Fixed dosing of intravenous tocilizumab case, the peripheral compartment is not identifiable [29] . However, the population estimates for CL and V were 0.0104 l h -1 and 4.83 l, respectively, which are in close agreement with previously published values [14] . Moreover, these data are in line with PK behaviour of other therapeutic monoclonal antibodies [30] . Our work also showed considerable variability for CL and V as previously reported [14] . The development of ADA has been reported as a common cause for lower drug serum concentrations, and consequently, a loss of effectiveness after initial response with a monoclonal antibody [31, 32] . However, response to tocilizumab has not been previously shown to be influenced by ADA [13] . Our results support the low incidence of ADA formation in RA patients treated with IV tocilizumab. In fact, none of the serum samples analysed showed the presence of ADA in our population. For this reason, the influence of ADA on tocilizumab CL could not be tested.
Body weight has previously been identified as a covariate influencing the PK of some other monoclonal antibodies [1, 14] . Approved tocilizumab dosing is based on body weight on the assumption that body-weight dosing would provide a more consistent exposure across patients. This is under the assumption that exposure is linearly related to body weight [33] . However, this relationship is far from linear for most monoclonal antibodies and as a consequence, this approach tends to overdose those patients with large body size while underdose patients with small body size [34, 35] . This tendency is clearly seen in Figure 2a , 2b and 2c. On the contrary, fixed-dosing may overdose patients with small body size and underdose patients with large body size.
Fixed dosing has already shown more consistent drug exposure than body-weight dosing for some monoclonal antibodies. Wang et al. [34] claimed that the best dosing approach is basically dependent on the steepness of the relationship between CL and weight. Thus, taking into account that their relationship is generally expressed as a power function covariate model, for exponent values below 0.5, fixeddosing provides less variability in exposure. In our study, we estimated this exponent on 0.360, which is below this 0.5 threshold and, of similar magnitude as that of Frey et al. [14] . Indeed, results from our simulations have shown that the distribution of cAUC values among weight groups after fixed dosing is much more uniform than after body-weight dosing (Figure 2) , thus supporting the use of fixed dosing. Moreover, a same trend in drug exposure was seen when simulations were conducted using the PK model of Frey et al., reconfirming that fixed dosing might be a better dosing strategy to achieve a more consistent drug exposure among all weight groups. In addition, we found a significant effect of CRP on tocilizumab CL. To our knowledge, this is the first time that an inflammatory biomarker such as CRP is included in a PK model for a monoclonal antibody used in RA treatment [1] . We believe it is a remarkable finding since higher values of CRP and ESR are common in clinical practice for those patients without a satisfactory response to treatment. As simulations results reflect, an increase in CRP value translates into a decrease in total drug exposure and thus, an increase in the percentage of patients at risk of being underdosed. Therefore, taking into account that high CRP values are usually seen at the beginning of the treatment, which would lead to a higher tocilizumab clearance, a starting dose of 8 mg kg -1 (or the equivalent fixed dose of 560 mg) seems to be more reasonable than 4 mg kg -1 (or 280 mg). Besides, it is probable that patients showing high values of CRP and not responding to treatment may be due to a higher drug CL, could benefit from a dose increment. However, according to Figure 3 , a dose of 560 mg might be enough to reach target in the majority of the patients if CRP levels were 2.8 mg dl -1 . By contrast, drug CL would be lower in those patients showing low CRP values.
Thus, a reduced tocilizumab dose might be enough for maintenance treatment. In short, our study confirms the weak relationship between CL and body weight for tocilizumab and provides evidence to support fixed dosing of IV tocilizumab in RA patients. CRP levels have been identified as a clinically important covariate to affect tocilizumab CL. Routine measurement in the clinical setting may open up the possibility of its application in the future to predict treatment response and optimal dose.
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